Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Open label study of sorafenib
Lung Cancer
DRUG: sorafenib
Response rate, January 2009|One-year survival, January 2009|Median survival, January 2009
Median progression-free survival, January 2009|Toxicities, January 2009
Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers (less than \< 100 cigarettes lifetime).